TORONTO, March 31 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ)
today provided an update of its retrospective review of bioanalytical studies
conducted in its Montreal facility from 2000 through 2004, following a recent
audit by the FDA. The audit identified a number of issues pertaining to the
effectiveness and management of the five-year review.
MDS is working diligently to meet all FDA expectations and is committed
to resolving all outstanding issues in a timely manner. In order to enhance
this effort, MDS is bringing in experienced project management from outside
the MDS Pharma Services division and will voluntarily wind down all commercial
bioanalytical liquid chromatography/mass spectrometry operations in Montreal.
This will allow for complete focus to accelerate the activities related to
this review. Commercial activities will continue in MDS Pharma Service's other
bioanalytical sites in Lincoln, Nebraska; Blainville, Quebec; Zurich,
Switzerland; and Sittingbourne, United Kingdom.
Stephen P. DeFalco, President and Chief Executive Officer, MDS Inc.
commented, "I am disappointed that we have not made progress at the rate
necessary on this review. We are enhancing the leadership and project
management of this effort in order to complete this review to the FDA's
satisfaction. Finalizing this effort in a high quality way is the top priority
for the Company."
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) has more than 8,800 highly skilled people
in 27 countries. We provide a diverse range of superior products and services
to increase our customers' speed, precision and productivity in the drug
development and disease diagnosis processes. We are a global, values-driven
life sciences company, recognized for our reliability and collaborative
relationships as we help create better outcomes in the treatment of disease.
Find out more at www.mdsinc.com or by calling 1-800-MDS-7222, 24 hours a day.
SOURCE MDS Inc.
-0- 03/31/2006
/CONTACT: Sharon Mathers, Vice-President, Investor Relations,
(416) 675-6777 ext. 2695, smathers@mdsintl.com/
(MDS. MDZ)
CO: MDS Inc.
ST: Ontario
IN: HEA
SU:
-30-
SB
-- TO175 --
2302 03/31/2006 08:00 EST http://www.prnewswire.com
